171 related articles for article (PubMed ID: 26227222)
1. Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.
Zhang J; Li B; Wu H; Ou J; Wei R; Liu J; Cai W; Liu X; Zhao S; Yang J; Zhou L; Liu S; Liang A
Tumour Biol; 2016 Jan; 37(1):531-9. PubMed ID: 26227222
[TBL] [Abstract][Full Text] [Related]
2. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis.
Guan S; Lu J; Zhao Y; Woodfield SE; Zhang H; Xu X; Yu Y; Zhao J; Bieerkehazhi S; Liang H; Yang J; Zhang F; Sun S
Oncotarget; 2017 May; 8(20):33666-33675. PubMed ID: 28430599
[TBL] [Abstract][Full Text] [Related]
3. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.
Wu J; Powell F; Larsen NA; Lai Z; Byth KF; Read J; Gu RF; Roth M; Toader D; Saeh JC; Chen H
ACS Chem Biol; 2013 Mar; 8(3):643-50. PubMed ID: 23272696
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of hyperthermia-induced apoptosis by 5Z-7-oxozeaenol, a TAK1 inhibitor, in A549 cells.
Li P; Zhao QL; Jawaid P; Rehman MU; Sakurai H; Kondo T
Cell Stress Chaperones; 2016 Sep; 21(5):873-81. PubMed ID: 27448221
[TBL] [Abstract][Full Text] [Related]
5. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase.
Ninomiya-Tsuji J; Kajino T; Ono K; Ohtomo T; Matsumoto M; Shiina M; Mihara M; Tsuchiya M; Matsumoto K
J Biol Chem; 2003 May; 278(20):18485-90. PubMed ID: 12624112
[TBL] [Abstract][Full Text] [Related]
6. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy.
Fan Y; Cheng J; Vasudevan SA; Patel RH; Liang L; Xu X; Zhao Y; Jia W; Lu F; Zhang H; Nuchtern JG; Kim ES; Yang J
Apoptosis; 2013 Oct; 18(10):1224-34. PubMed ID: 23700229
[TBL] [Abstract][Full Text] [Related]
7. Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells.
Acuña UM; Wittwer J; Ayers S; Pearce CJ; Oberlies NH; DE Blanco EJ
Anticancer Res; 2012 Jul; 32(7):2415-21. PubMed ID: 22753698
[TBL] [Abstract][Full Text] [Related]
8. TGFβ-activated Kinase 1 (TAK1) Inhibition by 5Z-7-Oxozeaenol Attenuates Early Brain Injury after Experimental Subarachnoid Hemorrhage.
Zhang D; Yan H; Li H; Hao S; Zhuang Z; Liu M; Sun Q; Yang Y; Zhou M; Li K; Hang C
J Biol Chem; 2015 Aug; 290(32):19900-9. PubMed ID: 26100626
[TBL] [Abstract][Full Text] [Related]
9. Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells.
Hrabe JE; O'Leary BR; Fath MA; Rodman SN; Button AM; Domann FE; Spitz DR; Mezhir JJ
Redox Biol; 2015 Aug; 5():319-327. PubMed ID: 26114584
[TBL] [Abstract][Full Text] [Related]
10. Effects of (5Z)-7-oxozeaenol on the oxidative pathway of cancer cells.
Acuña UM; Wittwer J; Ayers S; Pearce CJ; Oberlies NH; DE Blanco EJ
Anticancer Res; 2012 Jul; 32(7):2665-71. PubMed ID: 22753724
[TBL] [Abstract][Full Text] [Related]
11. Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade.
Choo MK; Kawasaki N; Singhirunnusorn P; Koizumi K; Sato S; Akira S; Saiki I; Sakurai H
Mol Cancer Ther; 2006 Dec; 5(12):2970-6. PubMed ID: 17172402
[TBL] [Abstract][Full Text] [Related]
12. Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization.
Wang JH; Tseng CL; Lin FL; Chen J; Hsieh EH; Lama S; Chuang YF; Kumar S; Zhu L; McGuinness MB; Hernandez J; Tu L; Wang PY; Liu GS
Theranostics; 2022; 12(2):657-674. PubMed ID: 34976206
[No Abstract] [Full Text] [Related]
13. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
14. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
15. Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB.
Li X; Yang X; Liu Y; Gong N; Yao W; Chen P; Qin J; Jin H; Li J; Chu R; Shan L; Zhang R; Zhang W; Wang H
Clin Cancer Res; 2013 Jun; 19(11):2917-28. PubMed ID: 23620411
[TBL] [Abstract][Full Text] [Related]
16. TGFβ1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity.
van Caam A; Madej W; Garcia de Vinuesa A; Goumans MJ; Ten Dijke P; Blaney Davidson E; van der Kraan P
Arthritis Res Ther; 2017 May; 19(1):112. PubMed ID: 28569204
[TBL] [Abstract][Full Text] [Related]
17. Constitutive association of TGF-beta-activated kinase 1 with the IkappaB kinase complex in the nucleus and cytoplasm of human neutrophils and its impact on downstream processes.
Ear T; Fortin CF; Simard FA; McDonald PP
J Immunol; 2010 Apr; 184(7):3897-906. PubMed ID: 20200282
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor β-activated kinase 1 inhibitor suppresses the proliferation in triple-negative breast cancer through TGF-β/TGFR pathway.
Zhang L; Fu Z; Li X; Tang H; Luo J; Zhang D; Zhuang Y; Han Z; Yin M
Chem Biol Drug Des; 2017 Sep; 90(3):450-455. PubMed ID: 28224764
[TBL] [Abstract][Full Text] [Related]
20. Targeting of TGF-β-activated protein kinase 1 inhibits chemokine (C-C motif) receptor 7 expression, tumor growth and metastasis in breast cancer.
Huang HL; Chiang CH; Hung WC; Hou MF
Oncotarget; 2015 Jan; 6(2):995-1007. PubMed ID: 25557171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
